Obermatt

Straumann

VTX:STMN · CH1175448666
Health Care Equipment & SuppliesLarge

360

40
EV / EBIT23
Price / Owner Earnings13
Owner Earnings Yield31
Dividend Yield53
Price/Sales21
EV / Gross Profit25
Price/Book16
Return on Capital95
Cash Return on Capital79
Return on Equity73
EBIT Margin86
Gross Profitability80
Cash Conversion30
Accruals31
Owner Earnings Margin57
Sales growth51
Profit Growth76
Long-Term EPS Growth54
Owner Earnings Growth30
Reinvestment13
Price momentum40
Debt load69
Refinancing44
Debt Payback100
Liquidity86
Analyst ratings34
Opinion Changes50
Price Target Upside34
Market mood49
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Straumann generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountrySwitzerland
IndustryHealth Care Equipment & Supplies
SizeLarge
TypePublic Company
ExchangeSWX
Founded2017
Employees4,528
ISINCH1175448666
Last UpdateApr 2, 2026
Themes
3D PrintingArtificial IntelligenceDentistrySurgeryBiomedical EngineeringHealth CareHospitalMedical

Description

Straumann Holding AG offers tooth replacement and orthodontic solutions. Business Strategy The company employs a multifaceted business strategy designed for long-term growth and market leadership in the dental industry. Key strategies include a str…

Analysis

Hope premium

Straumann Holding AG is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is expensive. The owner-earnings multiple stands at 53.2×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 19% a year, against analyst forecasts of 12%. The gap between price and consensus is worth watching: demanding expectations.

Growth is moderate; the safety picture is sturdy. The company scores 14/20 on our value-creation score: strong value creator.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
38
2023202420252026

All-time high

77

Jan 2023

All-time low

8

Jan 2024

Average rank

33

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
21
7
6
7
Price/Earnings
15
18
12
5
Price/Book
16
3
3
6
Dividend Yield
53
43
40
40
Value (overall)
21
14
9
13

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Straumann with its peers
Smith & Nephew
LSE:SN.
86
CountryUK
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →
LivaNova
NSQ:LIVN
76
CountryUK
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
Medartis Holding
SWX:MED
33
CountrySwitzerland
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Demant
CPH:DEMANT
25
CountryDenmark
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
Sonova
VTX:SOON
51
CountrySwitzerland
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →
Virbac
PAR:VIRP
58
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →